Continuous

From early RCT: robust inference of Remdesivir effect on time to clinical improvement

Now consider the previous example of Remdesivir but instead we are interested in the continuous outcome variable of time to clinical improvement. Figure 1. Time to clinical improvement in the Remdesivir example. Data from Table 3, Wang et al (2020). We can interpret the robustness of inference regarding Remdesivir’s effect on time to clinical improvement in following ways. Percent bias necessary to invalidate the inference To invalidate an inference, \(70.